Pericardial bioprosthetic heart valves were introduced into clinical practice more than 30 years ago. Unfortunately, the long-term results were initially disappointing, particularly with regard to the limited durability of the prosthesis. Clinical use of the Carpentier-Edwards pericardial (CEp) valve started in 1981, and a variety of new techniques of valve construction and anti-calcification treatments were applied in order to reduce the incidence of prosthesis failure. Subsequently, very satisfying long-term results have been achieved during the past years with the CEp valve. The study aim was to report the long-term outcome, of up to 18 years, with the CEp aortic valve at two Italian hospitals
Background The Mitroflow pericardial bioprosthesis (MPB) has been recently associated with a high in...
ObjectiveWe addressed the long-term results of the Medtronic Mosaic porcine prosthesis in the aortic...
BACKGROUND: Implantation of a bioprosthetic valve is a reasonable choice for patients aged \u3e65 ye...
Pericardial bioprosthetic heart valves were introduced into clinical practice more than 30 years ag...
Pericardial bioprosthetic heart valves were intro-duced into clinical practice more than 30 years ag...
International audienceAge is the most important factor for the durability of biological valves. With...
AbstractTo evaluate the function of the Carpentier-Edwards pericardial valve in the aortic position,...
International audienceBACKGROUND: We evaluate the clinical results of the Carpentier-Edwards supraan...
ObjectiveThe aim of the present study was to evaluate the very-long-term results of the Carpentier-E...
The long-term durability of the Carpentier-Edwards bioprosthesis in elderly patients exceeds 90% at ...
OBJECTIVES: The present study is aimed at evaluating the long-term outcomes (up to 12 years of follo...
The current status of valve replacement was reviewed by analyzing six groups of 100 consecutive pati...
AbstractObjectivesThis study compares the long-term performance of the Carpentier-Edwards (CE) porci...
OBJECTIVES: Outcome of aortic valve replacement may be influenced by the choice of bioprosthesis. Pe...
Aim. To evaluate long-term results of using xenogenic pericardial stentless prosthesis BioLAB KB/A.M...
Background The Mitroflow pericardial bioprosthesis (MPB) has been recently associated with a high in...
ObjectiveWe addressed the long-term results of the Medtronic Mosaic porcine prosthesis in the aortic...
BACKGROUND: Implantation of a bioprosthetic valve is a reasonable choice for patients aged \u3e65 ye...
Pericardial bioprosthetic heart valves were introduced into clinical practice more than 30 years ag...
Pericardial bioprosthetic heart valves were intro-duced into clinical practice more than 30 years ag...
International audienceAge is the most important factor for the durability of biological valves. With...
AbstractTo evaluate the function of the Carpentier-Edwards pericardial valve in the aortic position,...
International audienceBACKGROUND: We evaluate the clinical results of the Carpentier-Edwards supraan...
ObjectiveThe aim of the present study was to evaluate the very-long-term results of the Carpentier-E...
The long-term durability of the Carpentier-Edwards bioprosthesis in elderly patients exceeds 90% at ...
OBJECTIVES: The present study is aimed at evaluating the long-term outcomes (up to 12 years of follo...
The current status of valve replacement was reviewed by analyzing six groups of 100 consecutive pati...
AbstractObjectivesThis study compares the long-term performance of the Carpentier-Edwards (CE) porci...
OBJECTIVES: Outcome of aortic valve replacement may be influenced by the choice of bioprosthesis. Pe...
Aim. To evaluate long-term results of using xenogenic pericardial stentless prosthesis BioLAB KB/A.M...
Background The Mitroflow pericardial bioprosthesis (MPB) has been recently associated with a high in...
ObjectiveWe addressed the long-term results of the Medtronic Mosaic porcine prosthesis in the aortic...
BACKGROUND: Implantation of a bioprosthetic valve is a reasonable choice for patients aged \u3e65 ye...